Child Health and Infection With Low Density (CHILD) Malaria

• Status: Not yet recruiting
• Trial end date: 2027-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial will assess the long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzania

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, San Francisco
• Collaborators: Chan Zuckerberg Biohub; Ifakara Health Institute; National Institute of Allergy and Infectious Diseases (NIAID); Stanford University; Swiss Tropical & Public Health Institute
• Treatments: Artemether; Artemether, Lumefantrine Drug Combination; Lumefantrine

Criteria

Inclusion Criteria:

1. 6 months to 10 years of age

2. Residence in the study area

3. Agree to come to study clinic for any illness

4. Agree to avoid medications outside the study

Exclusion Criteria:

1. Another child from household already randomly selected for recruitment

2. Not able or refusal to provide informed consent

3. Need for emergency intervention

4. Antimalarial use within the last 28 days

5. Known history of chronic illness including diabetes mellitus, cancer, or stage 3 or 4 HIV/AIDS (per WHO criteria)

6. Contraindications to artemether-lumefantrine (AL) including history of allergic reaction, weight under 5 kg

7. Participation in another active/ongoing intervention trial